Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19466325 | 0.88 | FURIN (0.42) | FURINKISS1RNPY4RNPY1RNPY2R | |
| SCHEMBL19466303 | 0.88 | FURIN (0.42) | FURINKISS1RNPY4RNPY1RNPY2R | |
| SCHEMBL23425369 | 0.86 | MMP3 (0.39) | FURINKISS1RMMP3NPY4RNPY1R | |
| SCHEMBL16847753 | 0.85 | FURIN (0.43) | FURINSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL22064590 | 0.85 | FURIN (0.51) | FURINSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL23425378 | 0.84 | FURIN (0.39) | FURINMMP3NPY4RNPY1RNPY2R | |
| SCHEMBL15947589 | 0.83 | FAP (0.50) | FURINKISS1RNPY4RNPY1RNPY2R | |
| SCHEMBL26431147 | 0.83 | HTT (0.46) | FURINSMN1; SMN2HTT | |
| SCHEMBL23344152 | 0.82 | FURIN (0.50) | FURINSMN1; SMN2HTT | |
| SCHEMBL22266602 | 0.82 | ALB (0.43) | FURINSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326249-A1 | ANTIBODY-DRUG CONJUGATE OF AN ANTI-GLYPICAN-3 ANTIBODY AND A TUBULYSIN ANALOG, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326249-A1 | ANTIBODY-DRUG CONJUGATE OF AN ANTI-GLYPICAN-3 ANTIBODY AND A TUBULYSIN ANALOG, PREPARATION AND USES | SERPINA3, B3GAT3, ST3GAL3 | FURIN 2565/4885KISS1R 3127/4885MMP3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.